Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

ABSTRACT:

Importance

The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is still controversial.

Objective

To investigate the association of late onset MOGAD with moderate disability and relapse in Korean patients.

Design, setting, and participants

This nationwide, multicenter, retrospective cohort study included adult patients with a diagnosis of MOGAD according to the 2023 international diagnostic criteria between August 2018 and September 2024 across 28 hospitals in South Korea.

Exposure

Age at onset of MOGAD, categorized into adult-onset MOGAD (AO-MOGAD; 18-49 years) and late-onset MOGAD (LO-MOGAD; ≥50 years).

Main outcomes and measures

The primary outcomes were time to first relapse in patients with a disease du

SUBMITTER: Ju H 

PROVIDER: S-EPMC12905660 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature